Scarica l'app Stockscreener
2.69
1.10%
-0.03
Dopo l'orario di chiusura:
2.76
0.07
+2.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.72
Aprire:
$2.76
Volume 24 ore:
651.45K
Relative Volume:
0.76
Capitalizzazione di mercato:
$214.21M
Reddito:
-
Utile/perdita netta:
$-79.79M
Rapporto P/E:
-2.2378
EPS:
-1.2021
Flusso di cassa netto:
$-67.24M
1 W Prestazione:
-3.24%
1M Prestazione:
+33.17%
6M Prestazione:
+11.16%
1 anno Prestazione:
-25.28%
Intervallo 1D:
$2.655
$2.8799
Intervallo di 1 settimana:
$2.655
$3.15
Portata 52W:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Nome
Eledon Pharmaceuticals Inc
Settore
Industria
Telefono
949-238-8090
Indirizzo
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.69 | 214.21M | 0 | -79.79M | -67.24M | -1.2021 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Guggenheim | Buy |
| 2022-05-13 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Iniziato | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon's Tegoprubart Gets FDA's Orphan Drug Designation In Liver Transplantation; Stock Up - RTTNews
Eledon Pharma rises on FDA orphan status for lead asset - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
Eledon Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
NewcelX and Eledon partner for NCEL-101 programme - Yahoo Finance
Newcelx partners with Eledon to advance NCEL-101 - bioworld.com
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
Eledon Pharmaceuticals (ELDN) Enters Research Partnership to Com - GuruFocus
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - TradingView
Stem-cell islets plus immune drug: NewcelX, Eledon target Type 1 diabetes - Stock Titan
ELDN SEC FilingsEledon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock - MSN
Jobs Data: Is Eledon Pharmaceuticals Inc. stock a top pick in earnings seasonLong Setup & Daily Technical Forecast Reports - Naître et grandir
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - Sahm
Targets Report: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Institutional & Risk Controlled Swing Alerts - baoquankhu1.vn
Eledon execs join fireside chat at Leerink 2026 health conference - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Gainers: Whats Eledon Pharmaceuticals Incs historical returnBond Market & Daily Stock Trend Watchlist - baoquankhu1.vn
ELDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arkansas woman participates in clinical trial to cure type one diabetes - KARK
What makes Eledon Pharmaceuticals Inc. stock attractive todayGlobal Markets & High Accuracy Trade Signal Alerts - mfd.ru
Will Eledon Pharmaceuticals Inc. stock deliver shareholder valueWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
What’s the beta of Eledon Pharmaceuticals Inc. stock2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Can Eledon Pharmaceuticals Inc. expand its profit marginsGap Down & Free High Return Stock Watch Alerts - mfd.ru
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference - MarketBeat
Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path By Investing.com - Investing.com Canada
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Sahm
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Eledon Pharmaceuticals drops 10% on stock offering - MSN
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Up 3.6% – Should You Buy? - Defense World
Eledon Pharmaceuticals: Sustained Tegoprubart Efficacy, Differentiated Safety, and Upcoming Transplant Catalysts Support Buy Rating - TipRanks
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - Sahm
Eledon reports positive 24-month kidney transplant data for tegoprubart By Investing.com - Investing.com India
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Craig-Hallum Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating - 富途资讯
Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter Symposium - marketscreener.com
Eledon Pharmaceuticals (ELDN) to Reveal Promising Kidney Transpl - GuruFocus
Eledon reports positive 24-month kidney transplant data for tegoprubart - Investing.com
2-year transplant data: Eledon's tegoprubart shows no rejection in 8 patients - stocktitan.net
Surprises Report: Is SDHC stock a value trapEarnings Overview Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Loss Report: Is Eledon Pharmaceuticals Inc stock a good dividend stock2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Growth Value: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
What Caused Eledon Pharmaceuticals Stock (ELDN) to Drop 50% Today? - Intellectia AI
Eledon Pharmaceuticals Inc Azioni (ELDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):